ABR-238901

ABR-238901 is an orally active and potent S100A8/A9 blocker and inhibits S100A8/A9 interaction with its receptors RAGE (receptor for advanced glycation endproducts) and TLR4 (toll-like receptor 4) . ABR-238901 has the potential for myocardial infarction (MI) research[1][2][3].

Product Specifications

CAS Number

[1638200-22-2]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Toll-like Receptor (TLR)

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/abr-238901.html

Purity

98.92

Solubility

DMSO : 33.33 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=S(NC1=C(O)C(Cl)=CN=C1)(C2=CN=C(C(Br)=C2)OC)=O

Molecular Formula

C11H9BrClN3O4S

Molecular Weight

394.63

Precautions

H302, H315, H319, H335

References & Citations

[1]Kim De Veirman, et al. Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion. Cancer Immunol Res. 2017 Oct;5 (10) :839-846.|[2]Goran Marinković, et al. S100A9 Links Inflammation and Repair in Myocardial Infarction. Circ Res. 2020 Aug 14;127 (5) :664-676.|[3]A. Schiopu, et al. Short-term blockade of the S100A8/A9 alarmin in the immediate post-myocardial infarction period inhibits acute myocardial inflammation and preserves myocardial repair. European Heart Journal, Volume 38, Issue suppl_1, August 2017, ehx504.